^
Association details:
Biomarker:No biomarker
Cancer:Waldenstrom Macroglobulinemia
Drug:bortezomib (Proteasome inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
For patients who are intolerant to rituximab, subcutaneous bortezomib with dexamethasone can be considered as an alternate option to BDR (see Other Recommended Regimens for Primary Therapy)...